Amlodipine
Unchecked
Amlodipine
Norvasc, Katerzia
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Hypertension0, Stable angina0, Vasospastic angina0
Pharmacy
Starting dose
2.5-5 mg PO once daily; titrate to 10 mg/d
Preparations
2.5, 5, 10 mg tablets; 1 mg/mL oral suspension
US FDA Max
10 mg/d
Pharmacology
Routes
Oral
Onset
BP effect within 24 hours; full effect at 1-2 weeks (long half-life)
Duration
24 hours
Half-life
30-50 hours[1]
Bioavailability
64-90% (oral; not affected by food)[1]
Pregnancy
Limited data; case series and registries suggest no major teratogenicity but other antihypertensives (labetalol, nifedipine) are typically preferred.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Amlodipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type voltage-gated calcium channels in vascular smooth muscle, producing peripheral arterial vasodilation with minimal direct cardiac effect.0 The long half-life gives smooth, once-daily BP control with low rebound. CYP3A4 substrate; pedal edema is the characteristic, dose-related, non-fluid-overload side effect[1].
References
[edit | edit source]- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Norvasc (amlodipine besylate), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019787s055lbl.pdf